Eli Lilly and Alchemab Therapeutics have partnered to develop new therapies for amyotrophic lateral sclerosis (ALS). The ...

Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a ...

Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, ...

Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that it will present at J.P. Morgan's 43rd Annual Healthcare ...

Why Early Detection Is Crucial "Early treatment is not only more effective but also less invasive and more affordable," adds Dr. Todd Britten.

Biopharma innovator Alchemab Therapeutics, whose labs are in Cambridge UK, is collaborating with multinational pharma giant ...

The UK biopharma company Alchemab Therapeutics announced today that it has joined forces with Eli Lilly to discover, develop, ...

Aspen Neuroscience, Inc. has advanced its plans for automating production of ANPD001, including a capacity expansion for autologous manufacturing at its San Diego -based GMP facility.

Alchemab Therapeutics, a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies ...

UK-based Alchemab Therapeutics, a biopharma seeking to identify and develop naturally occurring therapeutic antibodies from ...

According to Jane Osbourn, chief scientific officer at Alchemab, a Cambridge-UK based antibody discovery biotech, the amyloid research provides a foundation for further treatments. Alchemab’s ...